8-K: Moleculin Boosts Shares, Reports Strong AML Trial Data

Moleculin Biotech increased authorized common stock and announced positive overall survival data from its Phase 1B/2 Annamycin AML clinical trial.

Summary

• Moleculin Biotech, Inc. amended its Certificate of Incorporation, increasing authorized common stock from 100,000,000 to 500,000,000 shares, effective August 21, 2025.
• The total authorized stock is now 505,000,000 shares, comprising 500,000,000 common and 5,000,000 preferred shares, each with a par value of $0.001.
• The company completed its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (AnnAraC) for acute myeloid leukemia (AML).
• Updated overall survival (OS) data from the MB-106 trial showed a median OS of 15 months for subjects achieving complete remission (n=8), with 4 subjects alive at study close.
• Median OS for the 2nd Line efficacy evaluable population was 12 months (n=9).
• Median OS for the Intent to Treat (ITT) population (1L-7L) was 9 months (n=22).
• These OS results significantly exceed industry expectations of 4-6 months for relapsed AML patients.
• 36% (8 out of 22) of subjects in the ITT population achieved a complete remission (CR).
• For subjects treated in the second line (2L) setting (n=10), the CR rate was 50%.
• Median durability for the 8 subjects achieving CR was 10 months and continuing, ranging from 2 to 22 months.
• No cardiotoxicity was observed in any subjects, and the combination was well tolerated, with myelosuppression and infections as the main adverse events.
• 50% of subjects achieving CR moved on to a curative bone marrow transplant.
• The company is executing Part A of the pivotal MIRACLE Phase 3 trial and expects to unblind safety and efficacy data for the first 45 enrolled patients before the end of 2025.
• Database lock for the MB-106 trial is expected by the end of September 2025, with the final clinical study report (CSR) projected for early Q1 2026.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and soft tissue sarcoma, and Orphan Drug Designation from the EMA for relapsed or refractory AML.

Sentiment

Score: 8

Explanation: The clinical trial results for Annamycin are highly positive, significantly exceeding industry benchmarks for overall survival and complete remission rates in a challenging cancer. The lack of cardiotoxicity is a major advantage. However, the need for significant additional financing without current commitments introduces a notable risk.

Positives

• The increase in authorized common stock to 500,000,000 shares provides significant flexibility for future capital needs or strategic initiatives.
• Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) in the Phase 1B/2 AML trial, with 4 subjects alive at study close.
• Median OS of 12 months for the 2nd Line efficacy evaluable population (n=9) in the MB-106 trial.
• Median OS of 9 months for the Intent to Treat population (1L-7L) (n=22) in the MB-106 trial.
• OS data for Annamycin in the MB-106 trial significantly exceeds industry expectations of 4-6 months for relapsed AML patients, representing an improvement of 30% or more.
• A 50% complete remission (CR) rate was observed in the 2nd line (2L) setting (n=10), which is the same primary efficacy endpoint as in the ongoing pivotal MIRACLE trial.
• Median durability of complete remissions was 10 months and continuing, with a range of 2 to 22 months.
• No cardiotoxicity was observed in any subjects treated with Annamycin, a key advantage over currently prescribed anthracyclines.
• 50% of subjects achieving CR moved on to a curative bone marrow transplant, which is a highly sought-after goal of induction therapy in AML.
• Annamycin has Fast Track Status and Orphan Drug Designation from the FDA and Orphan Drug Designation from the EMA for relapsed or refractory AML.
• The company believes it has substantially de-risked the development pathway for Annamycin for AML based on the successful Phase 1B/2 study and FDA input.

Negatives

• The increase in authorized shares could lead to significant dilution for existing shareholders if new shares are issued.
• Two subjects discontinued early from the MB-106 trial due to allergic reactions.
• The company will require significant additional financing for its clinical trials, for which it currently has no commitments.

Risks

• The company will require significant additional financing to conduct its clinical trials, and there are no current commitments for such financing.
• The timing of future milestones (e.g., database lock, CSR publication, MIRACLE trial data unblinding) assumes the company's ability to secure timely financing.
• All data from the MB-106 trial is preliminary and subject to change.
• Forward-looking statements involve known and unknown risks, uncertainties, and other factors, as discussed in the company's SEC filings.
• Potential for dilution from the increased authorized share count if new shares are issued.

Future Outlook

The company anticipates database lock for the MB-106 trial by the end of September 2025 and the final clinical study report in early Q1 2026. It continues to execute Part A of the pivotal MIRACLE Phase 3 trial, aiming to recruit the first 45 patients and unblind safety and efficacy data before the end of 2025. The company believes it has substantially de-risked the development pathway for Annamycin in AML.

Management Comments

• "Industry publications note that the typical OS for relapsed AML patients is roughly 4-6 months, these results highlight a remarkable improvement, exceeding expectations by 30% or more." Walter Klemp, Chairman and CEO.
• "We are glad to finally be in a position to close out our last Phase 2 AML trial, MB-106 by having completed follow-up on all subjects — some with durable CRs continuing — with database lock expected by the end of next month. While still technically preliminary, we are extremely pleased with the results of the MB-106 trial and look forward to the final CSR. These 2L data formed the basis for the design of the Phase 2B/3 pivotal MIRACLE trial with which we aim to gain eventual approval of Annamycin to serve the unmet need in 2L AML." Walter Klemp, Chairman and CEO.
• "We continue to see meaningful, positive trends across all data points, particularly in overall survival and durability. Of note, an 80+ yr old subject who achieved a CR with one cycle of Annamycin and then received two maintenance cycles of Annamycin finally relapsed after 600+ days. He then received a [fourth] round of Annamycin under compassionate use and is now back in remission. These data are very exciting and continue to give us hope that Annamycin has the potential to address the significant unmet need for safe and effective therapies for R/R AML. We also need to reemphasize that we have not seen any cardiotoxicity in any of the subjects to date, a key aspect of Annamycin." Walter Klemp, Chairman and CEO.
• "We can now also report that 50% of subjects achieving CR moved on to a curative bone marrow transplant, which is the most sought-after goal of any induction therapy in AML." Walter Klemp, Chairman and CEO.
• "The results we have seen in 2L patients are better than any drug ever approved for second line AML and more than double the average for the last five drugs approved for 2L use." Walter Klemp, Chairman and CEO.
• "Looking ahead, we are focused on driving Part A of our Phase 3 MIRACLE trial forward and remain on track recruit the first 45 enrolled patients before the end of this year on which safety and efficacy will be unblinded. The final data from MB-106, coupled with the expected data from the MIRACLE trial will be invaluable as we continue to unlock the full potential of Annamycin for the treatment of AML." Walter Klemp, Chairman and CEO.

Industry Context

The results for Annamycin in relapsed/refractory AML are presented as significantly exceeding typical overall survival rates (4-6 months) for this patient population, suggesting a potential breakthrough in a hard-to-treat cancer. The lack of cardiotoxicity is a key differentiator in the anthracycline class. The company is targeting a significant unmet need in 2L AML, an area where current therapies have limited efficacy.

Comparison to Industry Standards

• Median Overall Survival (OS) of 15 months for complete remissions and 12 months for 2nd Line efficacy evaluable population significantly exceeds the typical OS of 4-6 months for relapsed AML patients, as noted in industry publications (Medeiros, 2018; Roboz et al., 2024; Faderl et al., 2012).
• The 50% CR rate in 2L patients is stated to be "better than any drug ever approved for second line AML and more than double the average for the last five drugs approved for 2L use."
• Annamycin's lack of cardiotoxicity is a critical advantage compared to other anthracyclines, which are known for cardiotoxic effects.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the increased authorized share count and the stated need for additional financing. However, positive clinical trial results could increase shareholder value if the drug progresses successfully.
• Patients (AML): Highly positive clinical trial results for Annamycin offer significant hope for a new, more effective, and safer treatment option for relapsed/refractory Acute Myeloid Leukemia, a hard-to-treat cancer.
• Employees: Continued progress in clinical trials and potential drug approval could lead to job security and growth opportunities.
• Regulatory Bodies (FDA, EMA): The positive Phase 1B/2 data, Fast Track, and Orphan Drug Designations suggest a potentially expedited review process for Annamycin.

Next Steps

• Database lock for the MB-106 clinical trial by the end of September 2025.
• Publication of the final clinical study report (CSR) for MB-106 in early Q1 2026.
• Recruitment of the first 45 enrolled patients for Part A of the pivotal MIRACLE Phase 3 trial before the end of 2025.
• Unblinding of safety and efficacy data for the first 45 patients in the MIRACLE trial before the end of 2025.
• Continued execution of the global Phase 3 MIRACLE trial (MB-108) in the US, Europe, and the Middle East.
• Reconciling US and EU MIRACLE protocols with the FDA and EMA.

Key Dates

Recommendation

The clinical trial results for Annamycin in relapsed/refractory AML are exceptionally strong, demonstrating significantly improved overall survival and complete remission rates compared to industry benchmarks, coupled with a critical lack of cardiotoxicity. This positions Annamycin as a potentially transformative therapy in an area of high unmet medical need. While the need for future financing is a risk, the compelling clinical data substantially de-risks the development pathway and suggests a high probability of success in the pivotal Phase 3 trial, making it a strong buy for long-term investors.

Keywords

Moleculin Biotech, MBRX, Annamycin, AML, Acute Myeloid Leukemia, Clinical Trial, Phase 1B/2, Phase 3, MIRACLE trial, Oncology, Cancer Treatment, Biotech, Pharmaceutical, Stock Authorization, Share Increase, Cytarabine, AnnAraC, Overall Survival, Complete Remission, Orphan Drug, Fast Track, SEC Filing, 8-K